Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07215754) titled 'Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE Patients' on Oct. 2.

Study Type: Observational

Primary Sponsor: University of Pisa

Condition: Systemic Lupus Erythematosus

Recruitment Status: Recruiting

Date of First Enrollment: May 25, 2023

Target Sample Size: 300

Countries of Recruitment: Italy

To know more, visit https://clinicaltrials.gov/study/NCT07215754

Published by HT Digital Content Services with permission from Health Daily Digest....